Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome

American Journal of Cardiology

Volumn 113, Issue 1, 2014, Pages 12-16

  Klempfner, Robert ^a   Goldenberg, Ilan ^a   Fisman, Enrique Z ^b   Matetzky, Shlomi ^a   Amit, Uri ^a   Shemesh, Joseph ^a   Tenenbaum, Alexander ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b Cardiovascular Diabetology Research Foundation   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; NITRATE; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; BODY WEIGHT; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART RATE; HOSPITAL READMISSION; HUMAN; HYPERTENSION; ISCHEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; STENT THROMBOSIS; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ACUTE CORONARY SYNDROME; AGED; BEZAFIBRATE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; ISRAEL; MALE; MIDDLE AGED; MORBIDITY; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84890428078     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.08.033     Document Type: Article

References (29)

1. L. Rydén, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.J. de Boer, F. Cosentino, B. Jönsson, M. Laakso, K. Malmberg, S. Priori, J. Ostergren, J. Tuomilehto, I. Thrainsdottir, I. Vanhorebeek, M. Stramba-Badiale, P. Lindgren, Q. Qiao, S.G. Priori, J.J. Blanc, A. Budaj, J. Camm, V. Dean, J. Deckers, K. Dickstein, J. Lekakis, K. McGregor, M. Metra, J. Morais, A. Osterspey, J. Tamargo, J.L. Zamorano, J.W. Deckers, M. Bertrand, B. Charbonnel, E. Erdmann, E. Ferrannini, A. Flyvbjerg, H. Gohlke, J.R. Juanatey, I. Graham, P.F. Monteiro, K. Parhofer, K. Pyörälä, I. Raz, G. Schernthaner, M. Volpe, D. Wood, Task Force on DM and Cardiovascular Diseases of the European Society of Cardiology (ESC), and European Association for the Study of DM (EASD) Guidelines on diabetes mellitus, pre- diabetes mellitus, and cardiovascular diseases: executive summary. The Task Force on Diabetes Mellitus and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of DM (EASD) Eur Heart J 28 2007 88 136
2. M. Mazurek, J. Kowalczyk, R. Lenarczyk, T. Zielinska, A. Sedkowska, P. Pruszkowska-Skrzep, A. Swiatkowski, B. Sredniawa, O. Kowalski, L. Polonski, K. Strojek, and Z. Kalarus The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively Cardiovasc Diabetol 11 2012 78
3. M. Bartnik, K. Malmberg, and L. Rydén Management of patients with type 2 DM after acute coronary syndromes Diab Vasc Dis Res 2 2005 144 154
4. M.B. Kahn, R.M. Cubbon, B. Mercer, A.C. Wheatcroft, G. Gherardi, A. Aziz, V. Baliga, J.M. Blaxill, J.M. McLenachan, D.J. Blackman, J.P. Greenwood, and S.B. Wheatcroft Association of DM with increased all-cause mortality following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in the contemporary era Diab Vasc Dis Res 9 2012 3 9
5. P.F. Keller, D. Carballo, and M. Roffi Diabetes mellitus and acute coronary syndrome Minerva Med 101 2010 81 104
6. S. Sanon, R. Patel, C. Eshelbrenner, V.P. Sanon, M. Alhaddad, R. Oliveros, S.V. Pham, and R. Chilton Additive impact of diabetes mellitus on patients with metabolic syndrome and acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention Am J Cardiol 110 suppl 2012 13B 23B
7. A. Ceriello, and E. Motz Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes mellitus, and cardiovascular disease? The common soil hypothesis revisited Arterioscler Thromb Vasc Biol 24 2004 816 823
8. M.A. Creager, T.F. Luscher, F. Cosentino, and J.A. Beckman Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: part I Circulation 108 2003 1527 1532
9. M.E. Young, P. McNoulty, and H. Taegmeyer Adaptation and maladaptation of the heart in diabetes mellitus. Part II. Potential mechanisms Circulation 105 2002 1861 1870
10. The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
11. A. Tenenbaum, and E.Z. Fisman Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction Cardiovasc Diabetol 11 2012 125
12. T. Meade, R. Zuhrie, C. Cook, and J. Cooper Bezafibrate in men with lower extremity arterial disease: randomised controlled trial BMJ 325 2002 1139
13. K. Ikewaki, K. Noma, J. Tohyama, T. Kido, and S. Mochizuki Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia - a nuclear magnetic resonance study Int J Cardiol 101 2005 441 447
14. I.J. Jonkers, M.F. Mohrschladt, R.G. Westendorp, A. van der Laarse, and A.H. Smelt Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial Am J Med 112 2002 275 280
15. T. Teramoto, K. Shirai, H. Daida, and N. Yamada Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with DM: the J-BENEFIT study Cardiovasc Diabetol 11 2012 29
16. A. Madrid-Miller, L.A. Moreno-Ruiz, G. Borrayo-Sánchez, E. Almeida-Gutiérrez, D.F. Martínez-Gómez, and R. Jáuregui-Aguilar Impact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trial Cir Cir 78 2010 229 237
17. A. Tenenbaum, and E.Z. Fisman Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes mellitus prevention? Cardiovasc Diabetol 11 2012 140
18. R. Krysiak, A. Gdula-Dymek, and B. Okopien The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia Eur J Clin Pharmacol 67 2011 1109 1117
19. A. Tenenbaum, D. Medvedofsky, E.Z. Fisman, L. Bubyr, S. Matetzky, D. Tanne, R. Klempfner, J. Shemesh, and I. Goldenberg Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data PLoS One 7 2012 e35298
20. D.K. McGuire, H. Emanuelsson, C.B. Granger, E. Magnus Ohman, D.J. Moliterno, H.D. White, D. Ardissino, J.W. Box, R.M. Califf, E.J. Topol, and GUSTO IIb Investigators Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study Eur Heart J 21 2000 1750 1758
21. D.K. McGuire, L.K. Newby, M.V. Bhapkar, D.J. Moliterno, J.S. Hochman, W.W. Klein, W.D. Weaver, M. Pfisterer, R. Corbalán, M. Dellborg, C.B. Granger, F. Van De Werf, E.J. Topol, R.M. Califf SYMPHONY and 2nd SYMPHONY Investigators Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes Am Heart J 147 2004 246 252
22. S.M. Donahoe, G.C. Stewart, C.H. McCabe, S. Mohanavelu, S.A. Murphy, C.P. Cannon, and E.M. Antman Diabetes and mortality following acute coronary syndromes JAMA 298 2007 765 775
23. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz, P. Ganz, M.F. Oliver, D. Waters, A. Zeiher, B.R. Chaitman, S. Leslie, T. Stern Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial JAMA 285 2001 1711 1718
24. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene, and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
25. M. Ayaori, Y. Momiyama, Z.A. Fayad, A. Yonemura, R. Ohmori, T. Kihara, N. Tanaka, K. Nakaya, M. Ogura, S. Sawada, H. Taniguchi, M. Kusuhara, M. Nagata, H. Nakamura, and F. Ohsuzu Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia Atherosclerosis 196 2008 425 433
26. A. Tenenbaum, M. Motro, E.Z. Fisman, D. Tanne, V. Boyko, and S. Behar Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome Arch Intern Med 165 2005 1154 1160
27. I. Goldenberg, M. Benderly, U. Goldbourt BIP Study Group Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial Am Coll Cardiol 51 2008 459 465
28. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
29. D. Gavish, E. Leibovitz, I. Shapira, and A. Rubinstein Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety J Intern Med 247 2000 563 569